États-Unis · Plateformes & données · MarketBeat

Inovio Pharmaceuticals Q3 Earnings Call Highlights

Publié par MarketBeat · États-Unis il y a 26 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Inovio Pharmaceuticals (NASDAQ:INO) is preparing to launch its first approved product, VOCERYQ, after the Food and Drug Administration granted accelerated approval for the treatment of adults with recurrent respiratory papillomatosis, or RRP, the company said on its third-quarter earnings call. Chi

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Inovio Pharmaceuticals Q3 Earnings Call Highlights

Résumé détaillé

À lire aussi

Sonos expects $570M-$630M Q1 revenue as it targets 500 bps gross margin uplift by FY27 exit

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

Prediction: This Will Be AMD’s Stock Price After 1 Year

Five US states join FTC suit against Hims & Hers over privacy practices

Fed Governor Waller sees December hike likely, opens door to possible half-point increase

This Simple Salt Swap Could Save 3 Million Lives a Year

Inovio Pharmaceuticals Q3 Earnings Call Highlights

Résumé détaillé

Partager

À lire aussi

Sonos expects $570M-$630M Q1 revenue as it targets 500 bps gross margin uplift by FY27 exit

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

Prediction: This Will Be AMD’s Stock Price After 1 Year

Five US states join FTC suit against Hims & Hers over privacy practices

Fed Governor Waller sees December hike likely, opens door to possible half-point increase

This Simple Salt Swap Could Save 3 Million Lives a Year